We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,500
Open access books available

108,000
International authors and editors

1.7 M
Downloads

151
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Abstract

Paracetamol is the most widely used over-the-counter medication in the world. The mechanism of action of its analgesic effect was often considered as based on the mobilization of the cyclooxygenases and more recently on serotonergic pathways. A new metabolic pathway involving the generation of an active metabolite, AM404 (N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide), in the brain by the fatty acid amide hydrolase (FAAH) enzyme, was recently identified. This chapter describes experimental data that have shown the involvement of this metabolic pathway in the analgesic action of paracetamol and its relationship with the cyclooxygenase and serotonergic systems. It also explains how new targets and systems, such as the cannabinoid and vanilloid systems and the calcium channel receptor Cav3.2, play a role in the action of paracetamol. Finally, it suggests how research on the mechanism of the clinically relevant effects of this long-established analgesic could lead to new therapeutic pain strategies.

Keywords: paracetamol, para-aminophenol, AM404, pain, FAAH, CB1, TRPV1, Cav3.2, serotonin

1. Introduction

More than a century after its discovery, paracetamol (acetaminophen) is the most widely prescribed analgesic in the world. Although used as a treatment for moderate pain and fever for more than a century, the mechanisms of its analgesic action are poorly understood and are a topic of ongoing debate. This chapter presents and updates the preclinical data on the pharmacodynamics of the paracetamol. While the two main mechanisms are considered as based
on the inhibition of cyclooxygenases and/or the activation of the serotonergic system [1], we show that the endocannabinoid and vanilloid systems and the T-type calcium-channel Cav3.2 are emerging as new targets of its action via complex metabolic and neuronal pathways.

2. Paracetamol, a prodrug of which AM404 is the active metabolite

In 2005, Högestätt et al. [2] showed that paracetamol, following its hepatic deacetylation to p-aminophenol, is metabolized in the brain by the fatty acid amide hydrolase (FAAH) enzyme to form AM404 (N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide) (Figure 1).

After administration of deuterium-labeled paracetamol in rats, they detected deuterium-labeled AM404 and p-aminophenol in the brain. They further showed that formation of p-aminophenol was present in all tissues, with highest levels in the liver and that AM404 was mainly found in the brain. The latter results were confirmed in a recent study [3].

Incubation of brain homogenate with p-aminophenol in vitro but not with paracetamol (except at high doses) leads to the formation of AM404 [2]. This is not the case if brain homogenate is incubated with deuterium-labeled AM404, which is converted into deuterium-labeled p-aminophenol (Figure 1).

**Figure 1.** Metabolization of paracetamol into AM404. AM404: N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide. FAAH, fatty acid amide hydrolase.
homogenate is boiled, pretreated with PMSF (a broad-spectrum protease, esterase and amidi-
rase inhibitor [4]) or if brain homogenate comes from FAAH−/− mice. Incubation of isolated
FAAH with p-aminophenol and arachidonic acid leads to the formation of AM404. In vivo,
paracetamol does not produce AM404 in the brains of rats pretreated with PMSF or in
FAAH−/− mice.

We speculated that this metabolic pathway was involved in its analgesic action and decided,
therefore, to investigate the analgesic effect of paracetamol metabolites. Systemic administra-
tion of p-aminophenol or intracerebroventricular injection of AM404 produced an analgesic
effect in animals.

We then investigated the involvement of FAAH in the action of paracetamol using mice
deleted for the FAAH gene (genetic strategy) and systemic administration of PMSF or
URB597, nonspecific and specific FAAH inhibitors, respectively, (pharmacological strategy)
to inhibit the FAAH enzyme. Both strategies resulted in the abolition of paracetamol-induced
(1) brain synthesis of AM404 and (2) analgesic action [5]. Likewise, the analgesic effect and
brain formation of AM404 induced by p-aminophenol were decreased in FAAH−/− mice and in
rats pretreated with PMSF [6].

The involvement of FAAH in the action of paracetamol was observed in different pain tests
(paw pressure, von Frey, tail immersion and formalin tests) and modalities (thermal, mechan-
ical and chemical stimuli) [5–7]. However, the experiments were conducted in naive animals,
in a context far removed, therefore, from the clinical setting, in which paracetamol is used
for pathological pain, notably nociceptive pain [8, 9]. Thus, the involvement of FAAH in the
action of paracetamol was studied in a more relevant clinical context using an inflammatory
mouse model submitted to thermal and mechanical stimuli to assess allodynia and hyperal-
gesia. The anti-allodynic and anti-hyperalgesic effects of paracetamol observed in this model
were lost in FAAH−/− mice [10], which lend further weight to the involvement of the FAAH in
inflammation.

Although it is now generally acknowledged that the action of paracetamol is central rather
than peripheral, opinions still differ [11, 12]. FAAH is a ubiquitous enzyme [4]. Some authors
detected AM404 in blood after paracetamol administration [13]. We investigated the periph-
eral versus central involvement of FAAH in the action of paracetamol studying its effect with
an FAAH inhibitor that readily crosses the blood-brain barrier, URB597 and a peripherally
restricted FAAH inhibitor, URB937 [14, 15] (Figure 2A).

The fact that the analgesic action of paracetamol is maintained after URB937 administra-
tion and lost after URB597 treatment [10] shows that only brain and not peripheral, FAAH
is involved and thereby confirms the central action of paracetamol. As a counterproof, the
peripherally restricted FAAH inhibitor URB937 was intracerebroventricularly injected and
challenged with paracetamol (Figure 2B). A supra-spinal injection of URB937 in mice prior to
paracetamol reversed its analgesic actions.

All these results show that supra-spinal FAAH is required for the desired effect of the
paracetamol.
3. Diferent molecular targets of AM404

3.1. COX enzyme

The first historical hypothesis for the action of paracetamol, proposed by Flower and Vane, was the inhibition of COX [16]. In cell cultures, inhibition of COX by paracetamol was observed in different cell types, brain slices, or homogenates [16–18] with conflicting results [19]. Paracetamol seems to have only a weak inhibitory effect on prostaglandin production in cell culture, with IC_{50} values mostly around 100 μM [20]. In animals, paracetamol reduced prostaglandin in cerebrospinal fluid [21], the spinal cord [22] and the brain [23, 24]. Interestingly, AM404 was shown to be an inhibitor of COX on isolated COX-1 and COX-2 and in LPS-induced prostaglandin E\textsubscript{2} formation in RAW264.7 macrophages [2].

However, an orally administered analgesic dose of paracetamol (200 mg/kg) in mice did not affect brain prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) content, while a high intraperitoneal dose (300 mg/kg), which impairs mice locomotor activity, reduced the content of prostanoid levels in the brain (PGE\textsubscript{2}), kidneys (PGE\textsubscript{2}) and blood (thromboxane B\textsubscript{2}) [7]. Paracetamol has a different pharmacological profile from that of the competitive COX inhibitor ibuprofen. In a context of noninflammatory pain, ibuprofen did not reduce pain, whereas paracetamol did, as observed in the first phase of formalin tests, tail immersion and von Frey tests in mice [7]. Altogether, these results indicate that the analgesic action of paracetamol cannot be attributed to inhibition of COX. Furthermore, the inhibitory effect of paracetamol on COX observed by some authors seems more closely related to its hypothermic/antipyretic effects than to its analgesic action [21, 23].

Further studies are needed before the involvement of COX can be fully ruled out. A study showing that PGs measured in mice after administration of 200 mg of paracetamol were not
decreased was performed with naive animals [7]. In a neuroinflammatory context such as chronic pain, in which PGs contribute to the maintenance of the process, it is possible that repeated administration of paracetamol could induce an inhibition of COX and that such a mechanism could be involved in the analgesic action of paracetamol.

3.2. CB₁ receptor

AM404 is able to indirectly activate the cannabinoid receptor CB₁ by inhibiting the degradation [25] and reuptake [26, 27] of anandamide. Involvement of this receptor in the action of paracetamol was confirmed by a study showing that CB₁ knockout mice and rats pretreated with a specific CB₁ antagonist (AM251) were insensitive to paracetamol [5, 28]. Corroborating these results, we showed that the analgesic effect of p-aminophenol was also suppressed by AM251 [6]. Interestingly, it was shown in a neuropathic rat pain model that the synergic or additive antinociception of paracetamol with gabapentin, memantine, or tramadol was attenuated by pretreatment with AM251 [29]. In the same study, the intrinsic analgesic effect of gabapentin, memantine, or tramadol was not affected by CB₁ receptor antagonist. The involvement of CB₁ receptor seems independent of the potential inhibitory effect of AM404 on cannabinoid reuptake because the overall brain content of endocannabinoids (anandamide, 2-arachidonoylglycerol and palmitoylethanolamide) was not affected by an administration of paracetamol [7] or p-aminophenol [6] in mice or in rats. In addition, paracetamol does not bind directly CB₁ receptors [5]. Thus, the relationship between paracetamol and CB₁ remains to be elucidated.

3.3. TRPV1 receptor

Subsequent studies have shown that AM404 is also a potent activator of the capsaicin receptor TRPV1, as reported in patch-clamp experiments [30, 31]. Interestingly, local injection of AM404 in the paw of mice resulted in pain behavior (licking and lifting of the injected paw), a behavior not found in TRPV1⁻/⁻ mice [7]. The contribution of TRPV1 to the action of paracetamol has been explored by both genetic and pharmacological approaches to inhibit it. Results showed that a genetic inactivation of TRPV1 abolished the antinociceptive effects of paracetamol in the mouse formalin, von Frey and tail immersion tests [7]. Pharmacological blockade of TRPV1 by capsazepine in rats also suppressed the analgesic effect of paracetamol [7]. Observations made on paracetamol can be extended to p-aminophenol, since pretreatment with capsazepine in rats or administration in TRPV1⁻/⁻ mice prevented the antinociceptive effect of p-aminophenol [6]. Further, the analgesic effect of the intracerebroventricular injection of AM404 was lost in TRPV1⁻/⁻ mice [7]. In a calcium imaging experiment, human embryonic kidney (HEK) cells, which constitutively expressed FAAH, were transfected with TRPV1. AM404 induced intracellular calcium mobilization [30]. This response was not observed in cells pretreated with capsazepine or in cells that were not transfected with TRPV1. In agreement with the previous results, bath application of p-aminophenol also induced an increase in intracellular calcium, smaller and slower than that of AM404. The calcium increase induced by p-aminophenol was abolished in cells either pretreated with capsazepine or not transfected with TRPV1 [30]. The effect of TRPV1
was due to metabolization of \( p \)-aminophenol into AM404 because \( p \)-aminophenol-induced calcium mobilization was lost in cells pretreated with an FAAH inhibitor.

To accurately establish the location of the involvement of TRPV1 in paracetamol action, systemic administration of paracetamol was challenged with the selective blockade of TRPV1 in the brain. Injection of capsazepine into the lateral ventricle of mice abolished the antinociceptive effects of paracetamol [7]. Similarly, the antinociceptive activity of \( p \)-aminophenol was also lost in mice intracerebroventricularly preinjected with capsazepine [6]. Collectively, these findings identify brain TRPV1 as an important effector of paracetamol.

3.4. Cav3.2 calcium channel

Arachidonic-related compounds such as anandamide and 2-arachidonylelglycerol also interact with T-type calcium channels, especially the Cav3.2 subtype, an effect which mediates their analgesic property [32]. Silencing of Cav3.2 using oligonucleotide antisense [33], knockout mice [34], or pharmacological tools [35] resulted in impairment of pain in several pain tests, thereby confirming the strong role of this calcium channel in nociception. Because AM404 is the arachidonically metabolite of paracetamol, the role of Cav3.2 in paracetamol action was investigated [30]. Mice with deletion of the Cav3.2\(^{−/−}\) gene did not show any analgesic effect after paracetamol administration. In addition, the intracerebroventricular injection of AM404 did not induce an analgesic effect in these knockout mice.

To determine whether Cav3.2 in the brain is involved in the antinociceptive effect of paracetamol, we injected TTA-A2, a Cav3.2 blocker, intracerebroventricularly before administration of paracetamol. This treatment prevented the effect of paracetamol. Spinal involvement of Cav3.2 receptors was also studied by coadministering paracetamol with an intrathecal injection of TTA-A2. In contrast to the previous results, spinal blockade of Cav3.2 did not alter the analgesic effect of paracetamol, indicating that the antinociceptive effect of paracetamol is dependent on Cav3.2 located in the brain.

AM404 seems to have an indirect action because it only weakly inhibited Cav3.2 currents (IC\(_{50}\) = 13.7 \(\mu\)M) recorded in DRG neurons by a whole-cell patch clamp method [30]. By comparison, in the same assay, TTA-A2 had an IC\(_{50}\) of 9.0 nM. As expected, neither paracetamol nor \( p \)-aminophenol inhibited Cav3.2 currents.

We thus addressed the putative role of TRPV1, another calcium channel, in the mobilization of Cav3.2 in the analgesic action of paracetamol. To determine whether Cav3.2 was involved upstream or downstream of the action of TRPV1, we assessed the analgesic effect of intracerebroventricular injection of either TRPV1 agonist (capsaicin) or Cav3.2 antagonist (TTA-A2) in Cav3.2\(^{−/−}\) and TRPV1\(^{−/−}\) mice, respectively. Unlike the action of TTA-A2, which is maintained in TRPV1\(^{−/−}\) mice, the analgesic effect of capsaicin is lost in Cav3.2\(^{−/−}\) mice. These results show that brain TRPV1 activation needs Cav3.2 to mediate its action and suggest that the first target of AM404 is TRPV1.

To analyze more fully the relationship between TRPV1 and Cav3.2 channels, we performed electrophysiological recordings to study the Cav3.2 current in HEK cells stably expressing the
human Cav3.2 sequence. In these cells, the Cav3.2 current induced by depolarization was not affected by the bath application of capsaicin. However, when the cells were transfected with TRPV1, application of capsaicin suppressed the Cav3.2 current.

Altogether, these behavioral and electrophysiological findings show that Cav3.2 and TRPV1 act sequentially in concert to support the analgesic action of paracetamol [30].

4. Involvement of the serotonergic system

The involvement of the serotonergic system in the action of paracetamol was first described by Tjolsen et al. [37] in 1991 and by Pini et al. [38] in 1996. They demonstrated that the analgesic effect of paracetamol was reduced after lesion of the serotonergic bulbospinal pathway by 5,6-dihydroxytryptamine or total depletion of the central serotonin (5-HT) synthesis by p-chlorophenylalanine. These results were confirmed by another team using 5,7-dihydroxytryptamine [39]. Studies showing that paracetamol did not bind serotonin receptors [38, 40] prompted investigation of the mobilization of the serotonin neurotransmitter. The results showed that paracetamol increased in a dose-dependent manner the tissue concentrations of 5-HT in the cortex, hypothalamus, striatum, hippocampus and brainstem [38, 41].

Later studies showed that the spinal role of 5-HT₁₅, 5-HT₂₅, 5-HT₃C and 5-HT₅ receptor subtypes of serotonin receptors was involved in the action of paracetamol [39, 42–48]. However, investigations of the involvement of 5-HT₅ receptors yielded conflicting results in both animals [36, 42, 43, 47, 49, 50] and humans [51–54]. Interestingly, some of these studies showed that tropisetron, a nonspecific 5-HT₅ receptor antagonist, blocked the analgesic effect of paracetamol. Libert et al. [36] reported that the inhibitory effect of tropisetron on the action of paracetamol was not mediated by 5-HT₅ receptor because (1) other 5-HT₅ antagonists (granisetron and ondansetron) or (2) antisense oligodeoxynucleotides directed against 5-HT₅ receptors did not reverse the paracetamol-induced antinociceptive effect, which suggests the involvement of a spinal tropisetron-sensitive receptor that is not the 5-HT₅ receptor. More work is needed to identify this spinal receptor.

These results should be treated with caution. Serotonin receptor subtypes are differently involved in paracetamol action, depending on the nature of the stimulus. For example, spinal 5-HT₁₅ is involved in the analgesic action of paracetamol assessed in the formalin test (chemical stimulus) [44] but not in the paw pressure test (mechanical stimulus) [47]. This discrepancy could be explained by the differential efficacy and power of serotonin itself relative to the noxious tests [55]. In addition, the analgesic action of spinal-administered serotonin, like that of paracetamol, is suppressed in the formalin test [44, 45] and conserved in the paw pressure test [45, 56] following the inhibition of spinal 5-HT₁₅ receptors.

Like paracetamol, p-aminophenol elicited antinociception through the serotonergic bulbospinal pathway because its effect was reversed after lesion of the pathway by 5,7-dihydroxytryptamine [6]. In addition, spinal pretreatment of rats with WAY-100,635, a 5-HT₁₅ receptor antagonist and tropisetron, a nonspecific 5-HT₃A receptor antagonist, reduced the analgesic effect of p-aminophenol in the formalin test and the paw pressure test, respectively [6].
In light of evidence showing that paracetamol and \( p \)-aminophenol involved \( \text{CB}_1 \) receptors \([5]\), we investigated the serotonergic descending bulbospinal pathways and spinal 5-HT receptors in the antinociceptive effect of arachidonyl-2′-chloroethylamide (ACEA), a \( \text{CB}_1 \) receptor agonist. Our results showed that ACEA needed intact descending bulbospinal serotonergic pathways. Elsewhere, it was shown that the antinociceptive action of ACEA was suppressed by intrathecal injection of WAY-100,635 and tropisetron in the formalin test and the paw pressure test, respectively \([5]\). The similar serotonergic profiles of ACEA and paracetamol suggest that \( \text{CB}_1 \) receptor is an important link between paracetamol and serotonin in the production of antinociception.

5. New strategies to alleviate pain: pharmacological vectorization to target brain TRPV1 receptors

A high-concentration of capsaicin, an 8% patch (Qutenza®) is used clinically in Europe and the USA to alleviate neuropathic pain. It has been suggested that its action is due to defunctionalization of peripheral TRPV1 \([57]\). A systemic use of TRPV1 activators is to be avoided.

![Figure 3. FAAH-dependent formation of arvanil and olvanil from HMBA.](image-url)
because of their high toxicity, which entails the risk of, notably, pulmonary and cardiovascular adverse effects [58–60]. Metabolites of capsaicin could be mutagenic at very high doses as well [61]. On the basis of the study of the mechanism of action of paracetamol, we propose that brain TRPV1 should be specifically targeted for the pharmacological management of pain. New substrates of FAAH, analogs of paracetamol or p-aminophenol, can be synthesized with the idea that the arachidonic acid-conjugated metabolites would be a potent TRPV1 activators.

To validate this strategy, we studied, with E.D. Högestätt and P.M. Zygmunt, 4-hydroxy-3-methoxybenzylamine (HMBA), a primary amine analog of p-aminophenol. HMBA produced arvanil and olvanil in vitro in brain homogenates and in vivo in mouse brain [6] (Figure 3).

Administered in mice or in rats, it had an analgesic effect. Both the formation of arvanil and olvanil and the analgesic effect induced by HMBA were FAAH-dependent. These two effects were lower in FAAH−/− mice than in their FAAH+/+ littermates. Arvanil and olvanil are potent TRPV1 activators [6, 62]. This mechanism of action contributed to the action of HMBA because, like that of paracetamol and p-aminophenol, its analgesic effect was suppressed after a genetic (TRPV1−/− mice) or pharmacological (rats pretreated with capsazepine) blockade of TRPV1. Finally, as with paracetamol or p-aminophenol, intracerebroventricular injection of the TRPV1 blocker capsazepine prevented the antinociceptive effect of HMBA [6].

Taken together, these data provide evidence of concept for the use of a pharmacological vectorization strategy aimed specifically at activating supraspinal TRPV1 to alleviate pain.

6. Conclusion

All these recent findings prompt us to propose a novel view of paracetamol as a prodrug that needs to overcome a two-step metabolism to form AM404, its active metabolite, which mediates the analgesic effect via different supra-spinal targets to activate the bulbospinal serotonergic pathways (Figure 4).

Interestingly, the involvement of the FAAH metabolic pathway and cannabinoid system is specifically related to their antinociceptive action and not to their hypothermic/antipyretic action [63, 64].

Several other concepts of the mechanism of action of paracetamol have been forwarded, including the involvement of the opioid [13, 65–68], adrenergic [69–71] and cholinergic [72, 73] systems and that of nitric oxide synthetase [74–77], adenosine receptors [48, 78, 79] and calcium channel TRPA1 [80]. However, other studies have yielded conflicting findings notably concerning the opioid [40, 81, 82], adrenergic [37, 71, 83] and cholinergic [84] systems.

The huge number of putative targets for the action of paracetamol and the complex relationship between all the different neurological systems complicate the study of the molecular mechanism of its analgesic action. The relationship between the putative targets needs further
investigation to provide an overall view of the action of paracetamol. The understanding of the neurological and molecular actions of clinically used analgesics such as paracetamol could pave the way for the discovery of new analgesic compounds.

Figure 4. Proposed sequential mechanisms for the antinociceptive effect of paracetamol. (1) Deacetylation of paracetamol in $p$-aminophenol in the liver. (2) FAAH-dependent metabolism of $p$-aminophenol into AM404 in the brain. (3) Direct and/or indirect involvement of supra-spinal CB$_1$ receptors by this metabolite. (4) Reinforcement of the serotonergic bulbospinal pathways and (5) Involvement of spinal pain-suppressing serotonergic receptors. © Frédérique Koulkoff/Inserm from Mallet/UMR 1107/Neuro-Dol Inserm.
Author details

Christophe Mallet1,2*, Alain Eschalier1,2,3 and Laurence Daulhac1,2

*Address all correspondence to: christophe.mallet@udamail.fr

1 University of Clermont Auvergne, Fundamental and Clinical Pharmacology of Pain, Clermont-Ferrand, France
2 Inserm U 1107, Neuro-Dol, Clermont-Ferrand, France
3 CHU Clermont-Ferrand, Department of Pharmacology, Clermont-Ferrand, France

References


